Posted by Michael Wonder on 01 Nov 2025
Elahere receives positive reimbursement recommendation by Canada's Drug Agency for certain types of platinum-resistant ovarian cancers
30 October 2025 - Elahere was submitted for reimbursement review 180 days prior to Health Canada's approval in line with CDA-AMC's new Target Zero initiative.
Today, AbbVie has announced that Canada's Drug Agency (CDA-AMC), formerly CADTH, has recommended that Elahere (mirvetuximab soravtansine for injection), an antibody-drug conjugate, be reimbursed with conditions, for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
